Zhejiang Shengda Bio-Pharm Past Earnings Performance
Past criteria checks 0/6
Zhejiang Shengda Bio-Pharm's earnings have been declining at an average annual rate of -23.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.2% per year.
Key information
-23.9%
Earnings growth rate
-25.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.2% |
| Return on equity | -4.3% |
| Net Margin | -7.4% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Zhejiang Shengda Bio-Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 727 | -54 | 76 | 43 |
| 30 Sep 23 | 746 | -18 | 61 | 39 |
| 30 Jun 23 | 751 | -15 | 71 | 39 |
| 31 Mar 23 | 722 | 14 | 73 | 39 |
| 31 Dec 22 | 738 | 31 | 74 | 37 |
| 30 Sep 22 | 746 | 58 | 106 | 40 |
| 30 Jun 22 | 750 | 68 | 107 | 40 |
| 31 Mar 22 | 783 | 73 | 104 | 39 |
| 31 Dec 21 | 790 | 76 | 105 | 40 |
| 30 Sep 21 | 780 | 61 | 110 | 37 |
| 30 Jun 21 | 807 | 94 | 118 | 39 |
| 31 Mar 21 | 863 | 158 | 139 | 39 |
| 31 Dec 20 | 867 | 197 | 146 | 36 |
| 30 Sep 20 | 812 | 203 | 143 | 36 |
| 30 Jun 20 | 719 | 164 | 129 | 34 |
| 31 Mar 20 | 594 | 95 | 106 | 28 |
| 31 Dec 19 | 519 | 47 | 95 | 28 |
| 30 Sep 19 | 512 | 37 | 93 | 25 |
| 30 Jun 19 | 529 | 41 | 93 | 21 |
| 31 Mar 19 | 496 | 35 | 87 | 22 |
| 31 Dec 18 | 493 | 45 | 83 | 21 |
| 30 Sep 18 | 494 | 67 | 83 | 23 |
| 30 Jun 18 | 472 | 68 | 64 | 33 |
| 31 Mar 18 | 510 | 84 | 67 | 27 |
| 31 Dec 17 | 509 | 73 | 71 | 23 |
| 30 Sep 17 | 471 | 64 | 68 | 14 |
| 31 Dec 16 | 482 | 61 | 109 | 0 |
| 31 Dec 15 | 536 | 87 | 145 | 0 |
| 31 Dec 14 | 381 | 44 | 76 | 0 |
| 31 Dec 13 | 399 | 55 | 65 | 0 |
Quality Earnings: 603079 is currently unprofitable.
Growing Profit Margin: 603079 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603079 is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare 603079's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603079 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.01%).
Return on Equity
High ROE: 603079 has a negative Return on Equity (-4.27%), as it is currently unprofitable.